Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Indications Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04704154
What this trial is testing

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Who this might be right for
Solid Tumors
Bayer 175
Testing effectiveness (Phase 2)Active Not RecruitingNCT07280377
What this trial is testing

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Who this might be right for
Anal Cancer MetastaticSquamous Cell Carcinoma of the Anus Stage UnspecifiedPancreatic Cancer Metastatic+1 more
Oncolytics Biotech 122
Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Not applicableWithdrawnNCT03161613
What this trial is testing

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Who this might be right for
Multiple Indications Cancer
Bristol-Myers Squibb
Early research (Phase 1)Study completedNCT00729664
What this trial is testing

Multiple Ascending Dose (MDX1105-01)

Who this might be right for
Cancer, Multiple Indications
Bristol-Myers Squibb 281
Large-scale testing (Phase 3)Study completedNCT00522951
What this trial is testing

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Who this might be right for
Brain Metastases
Bayer 165
Early research (Phase 1)Study completedNCT02699515
What this trial is testing

MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors

Who this might be right for
Solid Tumors
Merck KGaA, Darmstadt, Germany 114
Early research (Phase 1)Study completedNCT02517398
What this trial is testing

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 600
Not applicableLooking for participantsNCT07295171
What this trial is testing

HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG

Who this might be right for
Multiple CancersMultiple Indications CancerFeasibility Studies
British Columbia Cancer Agency 27
Not applicableUnknownNCT02281188
What this trial is testing

Registry for Treatment of Upper Urinary Tract Tumours

Who this might be right for
Upper Urinary Tract Tumours
Clinical Research Office of the Endourological Society 2,451
Not applicableLooking for participantsNCT01351545
What this trial is testing

Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Who this might be right for
Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+14 more
Center for International Blood and Marrow Transplant Research 99,999
Early research (Phase 1)Study completedNCT03102320
What this trial is testing

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Who this might be right for
Neoplasms
Bayer 173